By: Tamara Yunusova, Staff Editor<\/p>\n
–<\/p>\n
On December 3, 2012, the U.S. Second Circuit Court of Appeals became the first court in the nation to authorize off-label drug promotion under the First Amendment.\u00a0 The heavily-disputed ruling, which is headed for further appeal, will have far-reaching implications for pharmaceutical companies and drug regulation policy. In a 2-1 decision, the Court of Appeals revoked the conviction of a sales representative who sold drugs for conditions not approved by the Food and Drug Administration (FDA).<\/p>\n
Alfred Caronia, a sales representative of Orphan Medical (later acquired by Jazz Pharmaceuticals), was promoting the prescription drug Xyrem (sodium oxybate).\u00a0 Listed as a Schedule III drug under the Controlled Substances Act, Xyrem is a central nervous system depressant which won FDA approval in 2002 to treat cataplexy and narcolepsy.2<\/sup>\u00a0 Caronia personally promoted Xyrem for insomnia, fibromyalgia, Parkinson\u2019s disease, chronic pain, general muscle disorders and other off-label uses to prescribers.6<\/sup>\u00a0 As a target of federal investigation in 2005, he was secretly recorded discussing the unapproved uses of the drug with a prescriber.1<\/sup>\u00a0 He was convicted in 2008 for introducing a misbranded drug into interstate commerce, a violation of the Food, Drug, and Cosmetic Act.1<\/sup><\/p>\n Contending that proscribing the provision of truthful and non-misleading information to prescribers for off-label use infringed upon his right to free speech, Mr. Caronia appealed to the higher courts.\u00a0 The violation of a constitutionally protected right was echoed by the Second Circuit\u2019s ruling which stated that \u201cthe government cannot prosecute pharmaceutical manufacturers and their representatives under the Food, Drug, and Cosmetic Act for speech promoting the lawful off-label use of an FDA approved drug.\u201d5<\/sup><\/p>\n \u201cIn the fields of medicine and public health, where information can save lives, it only furthers the public interest to ensure that decisions about the use of prescription drugs, including off-label usage, are intelligent and well-informed,\u201d wrote Circuit Judge Denny Chin.4<\/sup><\/p>\n While pharmaceutical representatives are barred from promoting drugs off-label, physicians are free to prescribe drugs for off-label conditions. \u00a0In that light, prohibiting sales representatives to promote drugs off label demands further scrutiny.\u00a0 Barring sales representatives from imparting truthful information about off-label uses when such uses are not illegal to begin with, essentially, prosecutes sales representatives for their speech, a violation of their First-Amendment rights.<\/p>\n About off-label prescribing rights, the Second Circuit ruling stated \u201cprohibiting off-label promotion by a pharmaceutical manufacturer while simultaneously allowing off-label use \u2018paternalistically\u2019 interferes with the ability of physicians and patients to receive potentially relevant treatment information; such barriers to information about off-label use could inhibit, to the public\u2019s detriment, informed and intelligent treatment decisions.\u201d6<\/sup><\/p>\n Whereas granting off-labeling rights leads to informed and intelligent decisions, opponents argue that legalizing off-label drug promotion will undermine the FDA\u2019s role in drug regulation.\u00a0 \u201cThe majority calls into question the very foundations of our century-old system of drug regulation,\u201d states dissenting Judge Debra Ann Livingston. \u201cIf drug companies were allowed to promote F.D.A. – approved drugs for unapproved uses, they would have little incentive to seek FDA approval for those uses.\u201d5<\/sup><\/p>\n The Caronia case is not the first of its kind to trigger the First Amendment reflex.\u00a0 In Sorrell vs. IMS Health, the U.S. Supreme Court repealed a Vermont law that forbade pharmaceutical companies to purchase prescribing information for marketing purposes, a practice known as data mining.1 <\/sup>\u00a0Ruling that data mining is protected under the first amendment, the Supreme Court voided the Vermont law that sought to prohibit this action.<\/p>\n With a verdict that staggers between a misdemeanor and a constitutional right, the Alfred vs. Caronia case poses some serious legal questions about where the boundaries of the First Amendment lie.\u00a0 Previously, off-labeling cases were settled as soon as it was proven that the drug was misbranded or promoted for unapproved purposes.\u00a0 Now, however, with the authorization of off-label promotion, litigation must go further to prove that the efforts to promote the drug were untruthful and misleading.<\/p>\n \u201cIt\u2019s very significant because it\u2019s going to make F.D.A., in its promotion cases focus on the kinds of speech that are more likely to harm consumers, such as false or misleading marketing versus something that is not approved\u201d said Gerald Masoudi, former chief counsel of the FDA. 5<\/sup><\/p>\n In addition to its accompanying changes in litigation, the Caronia case promises dynamic changes in traditional business policy.\u00a0 Prior to U.S. vs. Caronia, to avert the misbranding charge, pharmaceutical companies would invest millions of dollars annually on training programs.3<\/sup>\u00a0 For instance, in July 2012, GlaxoSmithKline agreed to pay $3 million in fines for off-label promotion of antidepressants.6\u00a0 \u00a0<\/sup>Aside from the great investments devoted to compliance programs, companies would spend hefty sums to settle allegations of off-label promotion.\u00a0 For its marketing of Risperidone (Risperdal) in August 2012, Johnson & Johnson pharmaceutical unit reached a $181 million consumer fraud settlement with 36 states and the District of Columbia.6<\/sup>\u00a0 Under the formidable Park doctrine, the government could prosecute individual executives for off-label speech made by members in the company irrespective of the executive\u2019s direct involvement or knowledge about the conduct.3<\/sup>\u00a0 With the legalization of off-label promotion, pharmaceutical companies will no longer face such penalties.<\/p>\n The Caronia case raises prominent questions about drug promotion, regulation, and policy. If approved, off-label promotion will broaden the knowledge of both patients and physicians of various drug therapies, a hallmark of intelligent decisions.<\/p>\n SOURCES:<\/span><\/b><\/p>\n By: Tamara Yunusova, Staff Editor – On December 3, 2012, the U.S. Second Circuit Court of Appeals became the first court in the nation to authorize off-label drug promotion under the First Amendment.\u00a0 The heavily-disputed ruling, which is headed for further appeal, will have far-reaching implications for pharmaceutical companies and drug regulation policy. In a…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,5],"tags":[343,2245,98,620,102,15,13,2229,2227,29,2232,94,35,314,20,97,363,1625,2149,47,2230,12,11,42,671,628,1756,240,453,16,1061,2148],"class_list":["post-1196","post","type-post","status-publish","format-standard","hentry","category-featured","category-news-politics","tag-and","tag-approval","tag-august","tag-cosmetic","tag-december","tag-disease","tag-drug","tag-drugs","tag-ebola-virus-disease","tag-editor","tag-fda","tag-february","tag-food","tag-for","tag-health","tag-july","tag-of","tag-or","tag-oxybate","tag-pain","tag-pharmaceutical","tag-pharmacist","tag-pharmacy","tag-public","tag-r","tag-right","tag-risperdal","tag-sodium","tag-system","tag-treatment","tag-with","tag-xyrem"],"views":806,"_links":{"self":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/1196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/comments?post=1196"}],"version-history":[{"count":0,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/1196\/revisions"}],"wp:attachment":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/media?parent=1196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/categories?post=1196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/tags?post=1196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n